Induction of 2G12 neutralizing antibody by plant-derived HIVgp145
植物来源的 HIVgp145 诱导 2G12 中和抗体
基本信息
- 批准号:7336641
- 负责人:
- 金额:$ 22.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-15 至 2009-01-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntibody FormationAwardBasic ScienceBindingBiochemicalBiologyCaviaCell LineComplexCultured CellsDevelopmentEndoplasmic ReticulumEpitopesExhibitsExposure toFaceFundingGaggingGlycoproteinsGoalsGolgi ApparatusGrantHIVHIV Envelope Protein gp120HIV InfectionsHIV vaccineHumanImmune responseIndividualInfectionMacacaMannoseMannosidaseModelingMolecular BiologyOralPathway interactionsPhasePlant ProteinsPlantibodiesPlantsPolysaccharidesProductionPropertyProteinsRecombinantsSIVSmall Business Funding MechanismsSmall Business Innovation Research GrantStandards of Weights and MeasuresSystemTestingTobaccoTransgenic OrganismsVaccinatedVaccinationVaccinesVaginaVariantconceptcostdesignenv Gene Productsimmunogenicimmunogenicityneutralizing antibodyneutralizing monoclonal antibodiesprogramsresponsescale upsimian human immunodeficiency virustraffickingtransmission processvaccine development
项目摘要
DESCRIPTION (provided by applicant): HIV infections and vaccines have historically been disappointingly poor at eliciting antibodies that neutralize primary isolates, thus the identification of a highly immunogenic neutralizing epitope/s is of the highest priority. Recently several broadly crossreactive human neutralizing monoclonal antibodies have been generated, which in combination, have been shown to passively protect macaques against vaginal SIV transmission. One of these MAbs, 2G12 is unique in that it recognizes an epitope that is comprised of a cluster of up to three oligomannose chains (residues 332, 392 and 295) on the outer face of gp120. Most infected individuals do not make 2G1like neutralizing antibodies, perhaps because the high mannose glycans are trimmed as the glycoproteins traffic through the secretory pathway. To test this concept, ProcCell has used the plant expression system to produce a high-mannose form of HIV gp145 by specifically targeting synthesis of HIV gp145 to the endoplasmic reticulum using a KDEL tag which blocks exit into the Golgi and exposure to mannosidases. These high-mannose HIV Env molecules exhibited stronger reactivity with 2G12 than CHO-derived Env, suggesting important structural differences between high mannose and secreted forms of the HIV Env. The aim of the current proposal is to produce the secreted form of the gp145 (comprising a mix of complex and high mannose glycans) and to compare the biochemical, functional and immunological properties of the high-mannose form of HIV gp145 Env with both plant and cell culture-derived secreted gp120/160 molecule. Plant- derived proteins will be produced in transgenic tobacco plants and cell lines, purified and used to immunize guinea pigs to assess differences in immunogenicity of the two glycoforms.
This approach represents an important new concept in optimizing vaccine efficiency by the induction of strong neutralizing 2G12-like antibodies and other potentially neutralizaing antibodies specific for yet unknown high mannose epitopes. It also highlights the usefulness of the plant expression systems in producing different glycoforms of proteins.
描述(由申请人提供):HIV感染和疫苗在历史上一直不太能引发中和原代分离株的抗体,因此鉴定高度免疫原性的中和表位是最优先的。最近已经产生了几种广泛交叉反应的人中和单克隆抗体,其组合已经显示出被动保护猕猴免受阴道SIV传播。这些MAb之一,2G 12是独特的,因为它识别由gp 120外表面上的一簇至多三个寡甘露糖链(残基332、392和295)组成的表位。大多数感染者不产生2G 1样中和抗体,可能是因为高甘露糖聚糖在糖蛋白通过分泌途径运输时被修剪。为了测试这一概念,ProcCell已经使用植物表达系统来产生高甘露糖形式的HIV gp 145,其通过使用KDEL标签特异性地将HIV gp 145的合成靶向到内质网,该KDEL标签阻断进入高尔基体和暴露于甘露聚糖酶。这些高甘露糖HIV Env分子与2G 12的反应性比CHO衍生的Env更强,表明高甘露糖和分泌形式的HIV Env之间存在重要的结构差异。本提案的目的是生产分泌形式的gp 145(包含复合物和高甘露糖聚糖的混合物),并比较高甘露糖形式的HIV gp 145 Env与植物和细胞培养物来源的分泌型gp 120/160分子的生物化学、功能和免疫学特性。植物来源的蛋白质将在转基因烟草植物和细胞系中产生,纯化并用于免疫豚鼠以评估两种糖型的免疫原性差异。
这种方法代表了通过诱导强中和2G 12样抗体和对未知高甘露糖表位特异性的其他潜在中和抗体来优化疫苗效率的重要新概念。它还强调了植物表达系统在生产不同糖型蛋白质中的有用性。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
- DOI:10.1371/journal.pone.0120451
- 发表时间:2015
- 期刊:
- 影响因子:3.7
- 作者:Rosenberg Y;Sack M;Montefiori D;Labranche C;Lewis M;Urban L;Mao L;Fischer R;Jiang X
- 通讯作者:Jiang X
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yvonne J Rosenberg其他文献
Yvonne J Rosenberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yvonne J Rosenberg', 18)}}的其他基金
Zwitterionic oxime (RS194B) to reverse advanced symptoms and lethality of organophosphate pesticide exposure
两性离子肟 (RS194B) 可逆转有机磷农药暴露的晚期症状和致死率
- 批准号:
9621314 - 财政年份:2018
- 资助金额:
$ 22.28万 - 项目类别:
Development of a handheld PEST-pen device for the rapid detection of organophosphate insecticides on food and clothing
开发手持式 PEST 笔装置,用于快速检测食品和衣物上的有机磷杀虫剂
- 批准号:
10079784 - 财政年份:2018
- 资助金额:
$ 22.28万 - 项目类别:
Development of a handheld PEST-pen device for the rapid detection of organophosphate insecticides on food and clothing
开发手持式 PEST 笔装置,用于快速检测食品和衣物上的有机磷杀虫剂
- 批准号:
10259769 - 财政年份:2018
- 资助金额:
$ 22.28万 - 项目类别:
Plant-derived HIV neutralizing mAbs for passive immunotherapy in newborn macaques
用于新生猕猴被动免疫治疗的植物源性 HIV 中和单克隆抗体
- 批准号:
9312216 - 财政年份:2016
- 资助金额:
$ 22.28万 - 项目类别:
Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatm
雾化重组丁酰胆碱酯酶预处理的功效和安全性
- 批准号:
8738719 - 财政年份:2009
- 资助金额:
$ 22.28万 - 项目类别:
Aerosol Delivery of a Recombinant Butyrylcholinesterase "BioShield" to Protect Ag
气溶胶递送重组丁酰胆碱酯酶“BioShield”以保护 Ag
- 批准号:
7612606 - 财政年份:2009
- 资助金额:
$ 22.28万 - 项目类别:
Passive immunotherapy using plant-derived broadly HIV-1 neutralizing MAbs to prev
使用植物来源的广泛 HIV-1 中和单克隆抗体进行被动免疫疗法来预防
- 批准号:
8210828 - 财政年份:2009
- 资助金额:
$ 22.28万 - 项目类别:
Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatm
雾化重组丁酰胆碱酯酶预处理的功效和安全性
- 批准号:
8523566 - 财政年份:2009
- 资助金额:
$ 22.28万 - 项目类别:
Aerosol Delivery of a Recombinant Butyrylcholinesterase "BioShield" to Protect Ag
气溶胶递送重组丁酰胆碱酯酶“BioShield”以保护 Ag
- 批准号:
7888255 - 财政年份:2009
- 资助金额:
$ 22.28万 - 项目类别:
Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatm
雾化重组丁酰胆碱酯酶预处理的功效和安全性
- 批准号:
9121644 - 财政年份:2009
- 资助金额:
$ 22.28万 - 项目类别:
相似海外基金
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9981001 - 财政年份:2017
- 资助金额:
$ 22.28万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9751102 - 财政年份:2017
- 资助金额:
$ 22.28万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9397073 - 财政年份:2017
- 资助金额:
$ 22.28万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
10223410 - 财政年份:2017
- 资助金额:
$ 22.28万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
- 批准号:
7951676 - 财政年份:2008
- 资助金额:
$ 22.28万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
- 批准号:
7606036 - 财政年份:2006
- 资助金额:
$ 22.28万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7375053 - 财政年份:2005
- 资助金额:
$ 22.28万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7201220 - 财政年份:2004
- 资助金额:
$ 22.28万 - 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
- 批准号:
6980810 - 财政年份:2003
- 资助金额:
$ 22.28万 - 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
- 批准号:
6419444 - 财政年份:2000
- 资助金额:
$ 22.28万 - 项目类别:














{{item.name}}会员




